821 related articles for article (PubMed ID: 36000843)
1. Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants.
Neerukonda SN; Wang R; Vassell R; Baha H; Lusvarghi S; Liu S; Wang T; Weiss CD; Wang W
J Virol; 2022 Sep; 96(17):e0114022. PubMed ID: 36000843
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern.
Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Stella AO; Kindinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Jean T; Foster CSP; Christ D; Hoppe AC; Munier ML; Darley D; Churchill M; Stark DJ; Matthews G; Rawlinson WD; Kelleher AD; Turville SG
EBioMedicine; 2022 Oct; 84():104270. PubMed ID: 36130476
[TBL] [Abstract][Full Text] [Related]
3. Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization.
Kim Y; Gaudreault NN; Meekins DA; Perera KD; Bold D; Trujillo JD; Morozov I; McDowell CD; Chang KO; Richt JA
Microbiol Spectr; 2022 Jun; 10(3):e0178921. PubMed ID: 35638818
[TBL] [Abstract][Full Text] [Related]
4. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS
Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668
[TBL] [Abstract][Full Text] [Related]
5. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic.
Hoffmann M; Krüger N; Schulz S; Cossmann A; Rocha C; Kempf A; Nehlmeier I; Graichen L; Moldenhauer AS; Winkler MS; Lier M; Dopfer-Jablonka A; Jäck HM; Behrens GMN; Pöhlmann S
Cell; 2022 Feb; 185(3):447-456.e11. PubMed ID: 35026151
[TBL] [Abstract][Full Text] [Related]
6. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity.
Meng B; Abdullahi A; Ferreira IATM; Goonawardane N; Saito A; Kimura I; Yamasoba D; Gerber PP; Fatihi S; Rathore S; Zepeda SK; Papa G; Kemp SA; Ikeda T; Toyoda M; Tan TS; Kuramochi J; Mitsunaga S; Ueno T; Shirakawa K; Takaori-Kondo A; Brevini T; Mallery DL; Charles OJ; ; ; ; Bowen JE; Joshi A; Walls AC; Jackson L; Martin D; Smith KGC; Bradley J; Briggs JAG; Choi J; Madissoon E; Meyer KB; Mlcochova P; Ceron-Gutierrez L; Doffinger R; Teichmann SA; Fisher AJ; Pizzuto MS; de Marco A; Corti D; Hosmillo M; Lee JH; James LC; Thukral L; Veesler D; Sigal A; Sampaziotis F; Goodfellow IG; Matheson NJ; Sato K; Gupta RK
Nature; 2022 Mar; 603(7902):706-714. PubMed ID: 35104837
[TBL] [Abstract][Full Text] [Related]
7. Ensemble-Based Mutational Profiling and Network Analysis of the SARS-CoV-2 Spike Omicron XBB Lineages for Interactions with the ACE2 Receptor and Antibodies: Cooperation of Binding Hotspots in Mediating Epistatic Couplings Underlies Binding Mechanism and Immune Escape.
Raisinghani N; Alshahrani M; Gupta G; Verkhivker G
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673865
[TBL] [Abstract][Full Text] [Related]
8. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization.
Cele S; Jackson L; Khoury DS; Khan K; Moyo-Gwete T; Tegally H; San JE; Cromer D; Scheepers C; Amoako DG; Karim F; Bernstein M; Lustig G; Archary D; Smith M; Ganga Y; Jule Z; Reedoy K; Hwa SH; Giandhari J; Blackburn JM; Gosnell BI; Abdool Karim SS; Hanekom W; ; ; von Gottberg A; Bhiman JN; Lessells RJ; Moosa MS; Davenport MP; de Oliveira T; Moore PL; Sigal A
Nature; 2022 Feb; 602(7898):654-656. PubMed ID: 35016196
[TBL] [Abstract][Full Text] [Related]
9. Determinants of Spike infectivity, processing, and neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2.
Pastorio C; Zech F; Noettger S; Jung C; Jacob T; Sanderson T; Sparrer KMJ; Kirchhoff F
Cell Host Microbe; 2022 Sep; 30(9):1255-1268.e5. PubMed ID: 35931073
[TBL] [Abstract][Full Text] [Related]
10. Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies.
Shah M; Woo HG
Front Immunol; 2021; 12():830527. PubMed ID: 35140714
[TBL] [Abstract][Full Text] [Related]
11. A structure-function analysis shows SARS-CoV-2 BA.2.86 balances antibody escape and ACE2 affinity.
Liu C; Zhou D; Dijokaite-Guraliuc A; Supasa P; Duyvesteyn HME; Ginn HM; Selvaraj M; Mentzer AJ; Das R; de Silva TI; Ritter TG; Plowright M; Newman TAH; Stafford L; Kronsteiner B; Temperton N; Lui Y; Fellermeyer M; Goulder P; Klenerman P; Dunachie SJ; Barton MI; Kutuzov MA; Dushek O; ; Fry EE; Mongkolsapaya J; Ren J; Stuart DI; Screaton GR
Cell Rep Med; 2024 May; 5(5):101553. PubMed ID: 38723626
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex.
Mannar D; Saville JW; Zhu X; Srivastava SS; Berezuk AM; Tuttle KS; Marquez AC; Sekirov I; Subramaniam S
Science; 2022 Feb; 375(6582):760-764. PubMed ID: 35050643
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 strains bearing Omicron BA.1 spike replicate in C57BL/6 mice.
Ogger PP; Martín MG; Jang S; Zhou J; Brown J; Sukhova K; Furnon W; Patel AH; Cowton V; Palmarini M; Barclay WS; Johansson C
Front Immunol; 2024; 15():1383612. PubMed ID: 38742107
[TBL] [Abstract][Full Text] [Related]
14. Evolution of Immune Evasion and Host Range Expansion by the SARS-CoV-2 B.1.1.529 (Omicron) Variant.
Ren W; Zhang Y; Rao J; Wang Z; Lan J; Liu K; Zhang X; Hu X; Yang C; Zhong G; Zhang R; Wang X; Shan C; Ding Q
mBio; 2023 Apr; 14(2):e0041623. PubMed ID: 37010428
[TBL] [Abstract][Full Text] [Related]
15. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.
Cao Y; Wang J; Jian F; Xiao T; Song W; Yisimayi A; Huang W; Li Q; Wang P; An R; Wang J; Wang Y; Niu X; Yang S; Liang H; Sun H; Li T; Yu Y; Cui Q; Liu S; Yang X; Du S; Zhang Z; Hao X; Shao F; Jin R; Wang X; Xiao J; Wang Y; Xie XS
Nature; 2022 Feb; 602(7898):657-663. PubMed ID: 35016194
[TBL] [Abstract][Full Text] [Related]
16. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion.
Li P; Liu Y; Faraone JN; Hsu CC; Chamblee M; Zheng Y-M; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu S-L
mBio; 2024 May; 15(5):e0075124. PubMed ID: 38591890
[TBL] [Abstract][Full Text] [Related]
17. Identification and Analysis of Monoclonal Antibodies with Neutralizing Activity against Diverse SARS-CoV-2 Variants.
Ishimaru H; Nishimura M; Tjan LH; Sutandhio S; Marini MI; Effendi GB; Shigematsu H; Kato K; Hasegawa N; Aoki K; Kurahashi Y; Furukawa K; Shinohara M; Nakamura T; Arii J; Nagano T; Nakamura S; Sano S; Iwata S; Okamura S; Mori Y
J Virol; 2023 Jun; 97(6):e0028623. PubMed ID: 37191569
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster.
Favresse J; Gillot C; Cabo J; David C; Dogné JM; Douxfils J
Int J Infect Dis; 2024 Jun; 143():107028. PubMed ID: 38583825
[TBL] [Abstract][Full Text] [Related]
19. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
[TBL] [Abstract][Full Text] [Related]
20. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.
Cameroni E; Bowen JE; Rosen LE; Saliba C; Zepeda SK; Culap K; Pinto D; VanBlargan LA; De Marco A; di Iulio J; Zatta F; Kaiser H; Noack J; Farhat N; Czudnochowski N; Havenar-Daughton C; Sprouse KR; Dillen JR; Powell AE; Chen A; Maher C; Yin L; Sun D; Soriaga L; Bassi J; Silacci-Fregni C; Gustafsson C; Franko NM; Logue J; Iqbal NT; Mazzitelli I; Geffner J; Grifantini R; Chu H; Gori A; Riva A; Giannini O; Ceschi A; Ferrari P; Cippà PE; Franzetti-Pellanda A; Garzoni C; Halfmann PJ; Kawaoka Y; Hebner C; Purcell LA; Piccoli L; Pizzuto MS; Walls AC; Diamond MS; Telenti A; Virgin HW; Lanzavecchia A; Snell G; Veesler D; Corti D
Nature; 2022 Feb; 602(7898):664-670. PubMed ID: 35016195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
